Results 141 to 150 of about 92,728 (309)
Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic,
Hill BT, Madanat YF, Smith MR, Almasan A
core
Advances in the modern treatment of chronic leukemia
Chronic leukemia consists of chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML). These diseases are generally incurable without hematopoietic stem cell transplant and were previously treated with chemotherapy and immunotherapy ...
Le, Tan Tai
core
Extracellular vesicles play pivotal roles in both healthy hematopoiesis and hematologic malignancies. They not only regulate hematopoietic stem cell fitness but also drive cancer progression and drug resistance. Their clinical potential spans from serving as non‐invasive biomarkers to acting as innovative therapeutic platforms and drug delivery ...
Fengyu Chen +5 more
wiley +1 more source
Reconceptualizing Aplastic Anemia—Seed, Worm, Soil
Aplastic anemia (AA) encompasses a group of hematological syndromes often misdiagnosed, resulting in a decrease in the overall blood cell count and representing a form of bone marrow failure. We reinterpret AA based on the “seed, worm, and soil” doctrine.
Xintong Xu +4 more
wiley +1 more source
Rituximab for the treatment of patients with chronic lymphocytic leukemia
M Gentile, E Vigna, C Mazzone, E Lucia, AG Recchia, L Morabito2, MG Bisconte, C Gentile, F Morabito1UOC di Ematologia, Azienda Ospedaliera di Cosenza, Italy; 2Servicio de Hematología y Hemoterapia, Hospital Universitario de Canarias, La Laguna,
C Mazzone, M Gentile, et al, E Vigna
core
Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication
Up‐to‐date, tumor markers are considered more helpful in the evaluation of treatment response and prognostication rather than diagnosis. Identifying a valid biomarker to help clinical management of hepatocellular carcinoma (HCC) is still a challenge, especially the alpha‐fetoprotein (AFP) negative HCC. This study evaluated the efficacy of serum Midkine
Yanfang Luo +3 more
wiley +1 more source
Interferon-alpha 2b early phase chronic Lymphocytic Leukemia with high risk for progression-first results of a randomized multicenter AIO-Study [PDF]
Knauf, W. U. +7 more
core +1 more source
Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center
ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres +4 more
wiley +1 more source
Impact of Co‐Morbid Immunocompromise in HPV‐Associated Oropharyngeal Squamous Cell Carcinoma
Among patients with surgically resected Human Papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), immunocompromised patients had significantly worse overall survival compared to the non‐compromised group; however, these exploratory findings should be interpreted cautiously.
Maxwell L. Weng +7 more
wiley +1 more source
Histiocytosis development and clinical variation through the lens of genomics
Abstract Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease.
Paul G Kemps +3 more
wiley +1 more source

